Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. (PubMed, CNS Drugs) - May 29, 2022 - "Clinical data on buprenorphine suggest its role as a safer alternative to traditional opioids, particularly in patients with non-cancer pain; while data on cebranopadol still require phase III study results to approve its introduction on the market. Other bifunctional MOR/NOP receptor ligands, such as BU08028, BU10038, and AT-121, are currently under pharmacological investigations and could represent promising analgesic agents for the future."
Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Neuralgia • Oncology • Pain • Psychiatry • Substance Abuse
|